Intraductal Carcinoma and Lobular Carcinoma in Situ Clinical Trial
Official title:
Management of Ductal Carcinoma in Situ (DCIS) or Pure Micro-invasive (DCIS-MI) Extended Breast, Axillary Node Sentinel Site (GAS) When the Diagnosis is Made by Biopsy and Treatment by Mastectomy Immediately. Descriptive Study
The rate of axillary dissection avoided in patients with Ductal Carcinoma in Situ (DCIS) and a mastectomy indication will be obtained by calculating the proportion of women with GAS in-patient population that will prove to be DCIS or DCIS-MI + CCI. A confidence interval of 95% will be deferred.
The rate of axillary dissection avoided in patients with DCIS and a mastectomy indication
will be obtained by calculating the proportion of women with GAS in-patient population that
will prove to be DCIS or DCIS-MI + CCI (after the final histology). A confidence interval of
95% will be deferred (binomial).
The rate of axillary dissection avoided in patients with DCIS-MI and an indication of
mastectomy is obtained by calculating the proportion of women with a GAS-all women with
DCIS-MI and an indication of mastectomy. A confidence interval of 95% will be deferred
(binomial).
;
Intervention Model: Single Group Assignment, Masking: Open Label